Milan

• A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) Ended
  2023-508404-37-00 3 2022-10-26 Non-muscle Invasive Bladder Cancer
• A phase 2/3 study to evaluate efficacy and clinical benefit of AT-007 with Sorbitol Dehydrogenase (SORD) Deficiency Ended
  2024-518250-16-00 10 2022-10-20 Sorbitol Dehydrogenase (SORD) Deficiency
• A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti–LAG-3) and INCAGN02390 (Anti–TI … Ended
  2023-504270-38-00 4 2022-10-18 In participants with PD-L1–positive and systemic therapy–naive R/M SCC
• A study to find out whether BI 1015550 improves lung function in people with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) Ended
  2024-512803-37-00 5 2022-10-05 Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
• A Phase 3 study to determine the Efficacy and Safety of Losmapimod in Treating Patients with Facioscapulohumeral Muscular Dystrophy (REACH) Ended
  2024-512737-33-00 5 2022-09-30 Facioscapulohumeral Muscular Dystrophy (FSHD)
• A Phase 3 Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease (Complication … Ended
  2024-516064-28-00 5 2022-09-27 Acute Graft Versus Host Disease
• Research study investigating how well NDec works in people with sickle cell disease Ended
  2023-508506-22-00 4 2022-09-22 Sickle cell disease
• Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended
  2023-505458-16-00 5 2022-09-13 Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpressio
• A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin … Ended
  2024-513992-42-00 10 2022-09-13 venous thromboembolism (VTE) in patients with gastrointestinal/genitou
• Phase 1/2 study of Nivolumab and Relatlimab in Combination with Bevacizumab in First-line HCC Ended
  2024-510649-33-00 9 2022-09-02 Advanced/metastatic hepatocellular carcinoma (HCC)
• A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache Ended
  2024-510729-24-00 6 2022-09-01 Chronic Migrane, Migrane, Medication Overuse Headache
• A Study of SGN-B7H4V in Advanced Solid Tumors Ended
  2023-503389-22-00 1 2022-08-31 Fallopian tube cancer
• A research study to look into how semaglutide, together with a lower dose of insulin glargine, compares to a higher dose of insulin glargine … Ended
  2024-510612-75-00 5 2022-08-31 Participants with T2D and overweight
• A Study of Relatlimab-nivolumab Fixed-dose Combination versus Regorafenib or TAS-102 in Participants with Later-lines of Metastatic Colorect … Ended
  2023-503797-21-00 5 2022-08-10 Metastatic Colorectal Cancer
• A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on … Ended
  2023-509569-19-00 10 2022-08-10 venous thromboembolism (VTE)
• Cohort study of human mpox virus disease Ended
  2022-501132-42-00 6 2022-08-02 Monkeypox virus disease
• A study to test whether BI 685509 alone or in combination with empagliflozin helps people with liver cirrhosis caused by viral hepatitis or … Ended
  2023-504257-12-00 4 2022-07-28 Portal hypertension
• A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian … Ended
  2023-505005-16-00 4 2022-07-27 Primary peritoneal cancer/Fallopian tube cancer
• Study of four-factor prothrombin complex concentrate, OCTAPLEX, in patients with acute major bleeding on direct oral anticoagulant (DOAC) th … Ended
  2024-515485-14-00 5 2022-07-07 Acute major bleeding in patients receiving DOAC therapy with factor Xa
• A Phase 2a, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington’s D … Ended
  2023-509835-26-00 4 2022-07-06 Huntington’s Disease
• Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) or A Phase 2b/3, Randomized, Controlled, 24-week Dose Ranging and … Ended
  2023-508734-34-00 10 2022-06-30 Pulmonary Arterial Hypertension (PAH)
• A Phase 2 study of durcabtagene autoleucel, B-cell maturation Antigen (BCMA)-directed CAR-T Cells in adult participants with relapsed and re … Ended
  2023-507140-37-00 4 2022-06-22 Adult patients with relapsed and refractory multiple myeloma
• Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovari … Ended
  2024-516166-11-00 5 2022-06-06 Platinum resistant recurrent or metastatic ovarian, fallopian, or prim
• A study to learn how well the treatment combination of finerenone and empagliflozin works and how safe it is compared to each treatment alon … Ended
  2023-506981-30-00 4 2022-05-25 Chronic kidney disease in type 2 diabetes mellitus

Showing 2,113–2,136 of 2,361 trials